- Home
- SUNE vs KZIA Comparison
SUNE vs KZIA Comparison
Compare SUNE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUNE
- KZIA
- Stock Information
- Founded
- SUNE 1969
- KZIA 1994
- Country
- SUNE United States
- KZIA Australia
- Employees
- SUNE N/A
- KZIA N/A
- Industry
- SUNE
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SUNE
- KZIA Health Care
- Exchange
- SUNE NYSE
- KZIA Nasdaq
- Market Cap
- SUNE 5.8M
- KZIA 5.1M
- IPO Year
- SUNE N/A
- KZIA 1999
- Fundamental
- Price
- SUNE $1.63
- KZIA $6.10
- Analyst Decision
- SUNE
- KZIA Strong Buy
- Analyst Count
- SUNE 0
- KZIA 2
- Target Price
- SUNE N/A
- KZIA $57.50
- AVG Volume (30 Days)
- SUNE 222.1K
- KZIA 2.6M
- Earning Date
- SUNE 08-05-2025
- KZIA 07-07-2025
- Dividend Yield
- SUNE N/A
- KZIA N/A
- EPS Growth
- SUNE N/A
- KZIA N/A
- EPS
- SUNE N/A
- KZIA N/A
- Revenue
- SUNE $56,279,194.00
- KZIA $1,549,158.00
- Revenue This Year
- SUNE N/A
- KZIA N/A
- Revenue Next Year
- SUNE N/A
- KZIA N/A
- P/E Ratio
- SUNE N/A
- KZIA N/A
- Revenue Growth
- SUNE N/A
- KZIA 248983.08
- 52 Week Low
- SUNE $1.38
- KZIA $2.86
- 52 Week High
- SUNE $30,400.00
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- SUNE N/A
- KZIA 50.96
- Support Level
- SUNE N/A
- KZIA $5.83
- Resistance Level
- SUNE N/A
- KZIA $9.60
- Average True Range (ATR)
- SUNE 0.00
- KZIA 1.19
- MACD
- SUNE 0.00
- KZIA -0.29
- Stochastic Oscillator
- SUNE 0.00
- KZIA 18.39
About SUNE SUNATION ENERGY INC
SUNation Energy Inc provides households with sustainable solar energy, back-up power and security, control and predictability, and cost savings. The company provides a full range of installation services, including design, engineering, procurement, permitting, construction, grid connection, warranty, monitoring, and maintenance of residential solar energy systems. It also offers battery storage to customers in select markets and serves a limited number of enterprise customers.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.